Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Strategic Alliance Partners

December 26, 2019

Ramy Sedhom, MD, looks back on his first year of oncology fellowship and shares advice for first-year fellows and trainees.

December 19, 2019

Research into the mechanisms that promote resistance to immune checkpoint blockade therapies suggests the need for new strategies for patients with immunorefractory disease.

November 14, 2019

Ashwani Rajput, MD, a cancer surgeon and researcher with a special interest in health care disparities, has been appointed director of the Kimmel Cancer Center at Johns Hopkins for the Washington, DC, region.

September 06, 2019

Mark James Levis, MD, PhD, program leader of Hematologic Malignancies and Bone Marrow Transplant Program at Sidney Kimmel Comprehensive Cancer Center, and professor of oncology, Johns Hopkins Medicine, discusses an analysis of gilteritinib in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia harboring other common co-mutations or a high FLT3-internal tandem duplication allelic ratio.

May 30, 2019

Benjamin P. Levy, MD, assistant professor of oncology, clinical director of Medical Oncology, Sidney Kimmel Cancer Center and Johns Hopkins Medicine, discusses the outlook for patients with oncogene-driven non–small cell lung cancer.

May 22, 2019

Benjamin P. Levy, MD, assistant professor of oncology, clinical director of Medical Oncology, Sidney Kimmel Cancer Center and Johns Hopkins Medicine, discusses the benefits of liquid biopsies in non–small cell lung cancer.

March 29, 2019

Benjamin P. Levy, MD, assistant professor of oncology, clinical director of Medical Oncology, Sidney Kimmel Cancer Center and Johns Hopkins Medicine, discusses the use of entrectinib in patients with NTRK-mutant and ROS1-rearranged non–small cell lung cancer.

March 13, 2019

Nilofer Saba Azad, MD, discusses data from 3 recent pivotal trials have influenced practice and/or warrant consideration when treating patients with localized pancreatic cancer.

March 11, 2019

Jarushka Naidoo, MBBCh, assistant professor of oncology, Johns Hopkins University, discusses considerations for managing immune-related adverse events in patients with non–small cell lung cancer.

March 06, 2019

Ana Maria Cristina De Jesus-Acosta, MD, discusses somatostatin analogs and peptide receptor radionucleotide therapy, and spoke to the discussion regarding the optimal sequence of therapy in patients with neuroendocrine tumors.

February 14, 2019

Julie R. Brahmer, MD, discusses advances made with immunotherapy in the lung cancer space, highlights challenges that still need to be addressed, and sheds light on ongoing research designed to determine treatment approaches beyond PD-1/PD-L1 and CTLA-4 inhibition

February 13, 2019

Julie R. Brahmer, MD, co-director of the Upper Aerodigestive Department in the Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, discusses the potential for immunotherapy beyond PD-1 and PD-L1 checkpoints in non–small cell lung cancer.

January 28, 2019

Amol K. Narang, MD, discusses recent advances made in the treatment of pancreatic cancer and explained how radiation oncology can be used to provide further clinical benefit to this patient population.

December 27, 2018

The new standard of care for the frontline treatment of patients with extensive-stage small cell lung cancer should be atezolizumab and chemotherapy, based on results from the IMpower133 trial.

September 10, 2018

Matthew Ladra, MD, MPH, discusses the treatment of patients with esthesioneuroblastoma, emphasizing the need for collaboration in this rare malignancy.

September 06, 2018

Farah Succaria, MD, postdoctoral fellow, Johns Hopkins Medicine, discusses targetable immune checkpoints in head and neck squamous cell carcinoma.

July 12, 2018

Matthew Ladra, MD, director, Pediatric Radiation Oncology, Johns Hopkins Kimmel Cancer Center at Sibley Memorial Hospital, discusses the treatment of esthesioneuroblastoma in children.

June 28, 2018

Suzanne L. Topalian, MD, director, Melanoma Program, professor of Surgery and Oncology, Johns Hopkins Medicine, discusses the immunosuppressive microenvironment of nasopharyngeal cancer.

June 09, 2018

Evanthia Roussos Torres, MD, oncology fellow, Johns Hopkins University School of Medicine, discusses the importance of preclinical models in HER2-positive breast cancer.

May 25, 2018

Farah Succaria, MD, postdoctoral fellow, Johns Hopkins Medicine, discusses the potential for combination immunotherapy in the treatment of patients with head and neck cancer.